Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIGX1094 + fulzerasib
- Development stage
- Unknown
- Lead developer
- Signet Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SIGX1094 + fulzerasib (Dupert) is an investigational combination therapy consisting of SIGX1094, a first-in-class small molecule dual inhibitor of focal adhesion kinase (FAK) and proto-oncogene tyrosine-protein kinase Src (SRC), and fulzerasib, an approved small molecule inhibitor of KRAS G12C. Developed by Signet Therapeutics in collaboration with Innovent Biologics, this combination is designed to target KRAS-G12C mutant non-small cell lung cancer (NSCLC). By combining FAK/SRC inhibition with KRAS G12C inhibition, the therapy aims to overcome resistance mechanisms and fibrotic microenvironments associated with KRAS-mutated tumors. The combination is currently in Phase II/III clinical development in China.
- Other names
- SIGX1094 + DupertSIGX1094 + GFH925SIGX1094 + IBI351SIGX1094 + fulzerasibSIGX1094 + 氟泽雷塞SIGX1094 + 达伯特fulzerasib + SIGX1094氟泽雷塞 + SIGX1094达伯特 + SIGX1094
02
Targets
FAK (Focal adhesion kinase)KRAS (Kirsten rat sarcoma viral oncogene homolog)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on SIGX1094 + fulzerasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIGX1094 + fulzerasib.